Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:INCR NASDAQ:INKT NASDAQ:MREO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.00-99.9%$0.42$0.00▼$3.42$16K-1.8338,653 shs313 shsINCRInterCure$0.96-3.0%$0.96$0.68▼$1.77$52.49M1.3952,788 shs8,190 shsINKTMiNK Therapeutics$11.23-1.6%$11.50$8.48▼$30.64$55.92M0.47154,888 shs7,472 shsMREOMereo BioPharma Group$0.32+2.2%$0.30$0.20▼$2.37$51.24M0.355.78 million shs671,496 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%-1.58%-29.13%-32.72%-79.11%INCRInterCure+4.21%+2.60%+13.27%+32.23%-36.13%INKTMiNK Therapeutics+2.33%+7.44%-5.07%-11.82%-71.90%MREOMereo BioPharma Group-2.18%-6.13%+2.95%-7.32%-81.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.00-99.9%$0.42$0.00▼$3.42$16K-1.8338,653 shs313 shsINCRInterCure$0.96-3.0%$0.96$0.68▼$1.77$52.49M1.3952,788 shs8,190 shsINKTMiNK Therapeutics$11.23-1.6%$11.50$8.48▼$30.64$55.92M0.47154,888 shs7,472 shsMREOMereo BioPharma Group$0.32+2.2%$0.30$0.20▼$2.37$51.24M0.355.78 million shs671,496 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals0.00%-1.58%-29.13%-32.72%-79.11%INCRInterCure+4.21%+2.60%+13.27%+32.23%-36.13%INKTMiNK Therapeutics+2.33%+7.44%-5.07%-11.82%-71.90%MREOMereo BioPharma Group-2.18%-6.13%+2.95%-7.32%-81.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 1.50ReduceN/AN/AINCRInterCure 1.00SellN/AN/AINKTMiNK Therapeutics 2.50Moderate Buy$35.00211.69% UpsideMREOMereo BioPharma Group 2.25Hold$3.25912.46% UpsideCurrent Analyst Ratings BreakdownLatest ANEB, MREO, INKT, and INCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/6/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/2/2026MREOMereo BioPharma Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/17/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/10/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/27/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.005/12/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/12/2026MREOMereo BioPharma Group BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.00(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/AINCRInterCure$78.47M0.67N/AN/A$2.11 per share0.45INKTMiNK TherapeuticsN/AN/AN/AN/A($3.03) per shareN/AMREOMereo BioPharma Group$500K102.48N/AN/A$0.26 per share1.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%9/23/2026 (Estimated)INCRInterCure-$10.37M$0.0332.00N/AN/AN/AN/AN/AN/AINKTMiNK Therapeutics-$12.49M-$2.84N/AN/AN/AN/AN/A-118.57%8/13/2026 (Estimated)MREOMereo BioPharma Group-$41.88M-$0.05N/A16.05N/AN/A-81.28%-70.45%8/11/2026 (Estimated)Latest ANEB, MREO, INKT, and INCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026MREOMereo BioPharma Group-$0.01N/AN/AN/A$3.50 millionN/A5/15/2026Q1 2026INKTMiNK Therapeutics-$0.77-$0.57+$0.20-$0.57N/AN/A5/12/2026Q1 2026MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.05$11.67 millionN/A4/30/2026Q4 2025INCRInterCureN/A-$0.10N/A-$0.10N/A$23.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A6.246.24INCRInterCure0.201.480.97INKTMiNK TherapeuticsN/A1.381.38MREOMereo BioPharma GroupN/A6.486.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%INCRInterCure8.34%INKTMiNK Therapeutics2.87%MREOMereo BioPharma Group62.83%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%INCRInterCureN/AINKTMiNK Therapeutics20.40%MREOMereo BioPharma Group6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals440.79 million7.91 millionNot OptionableINCRInterCure35054.68 millionN/AOptionableINKTMiNK Therapeutics304.98 million3.97 millionNo DataMREOMereo BioPharma Group40159.62 million149.24 millionOptionableANEB, MREO, INKT, and INCR HeadlinesRecent News About These CompaniesMereo BioPharma Group Corporate Event Calendar | NASDAQ:MREO41 minutes ago | benzinga.comShort Interest in Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Decreases By 34.5%July 4, 2026 | americanbankingnews.comMereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Given Consensus Recommendation of "Hold" by BrokeragesJuly 4, 2026 | americanbankingnews.com4basebio Announces Appointment of Chief Financial Officer and Board ChangesMay 14, 2026 | globenewswire.comMereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 12, 2026 | globenewswire.comMereo BioPharma Group plc Sponsored ADRApril 19, 2026 | edition.cnn.comWe're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash WiselyApril 7, 2026 | finance.yahoo.comMREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc ...April 6, 2026 | gazettextra.comGClass Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join – Contact Levi & KorsinskyApril 6, 2026 | globenewswire.comMREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREOApril 6, 2026 | globenewswire.comMREO DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREOApril 6, 2026 | newsfilecorp.comNMEREO LAWSUIT DEADLINE TODAY: Bragar Eagel & Squire, P.C. Urges Mereo BioPharma Stockholders with Large Losses to Contact the Firm Regarding Their RightsApril 6, 2026 | globenewswire.comMREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026April 6, 2026 | businesswire.comMereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREOApril 6, 2026 | prnewswire.comMREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law FirmApril 6, 2026 | prnewswire.comMREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud LawsuitApril 5, 2026 | prnewswire.comMREO DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREOApril 5, 2026 | newsfilecorp.comNMREO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026April 5, 2026 | newsfilecorp.comNMREO DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREOApril 4, 2026 | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor HarmApril 3, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANEB, MREO, INKT, and INCR Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$0.0004 -0.34 (-99.88%) As of 01:33 PM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.InterCure NASDAQ:INCR$0.96 -0.03 (-3.03%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.MiNK Therapeutics NASDAQ:INKT$11.23 -0.18 (-1.59%) As of 02:21 PM Eastern This is a fair market value price provided by Massive. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Mereo BioPharma Group NASDAQ:MREO$0.32 +0.01 (+2.23%) As of 02:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s AI Spending Question Looms Over Q2 Earnings 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger 3 Gold Stocks Under $5 With Massive Upside CleanSpark Inks a $6.6B AI Lease to Become a Digital Landlord Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet Blueprint for a Billion: Nebius Group Secures the AI Floor Marriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
